AIVITA Biomedical is a biotechnology company developing personalized vaccines that target multiple pathogens and tumor-initiating cells—the seed of all cancers—using our autologous personal immunotherapy platform. Founded in 2016 by pioneers in the stem cell industry, AIVITA utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial products and therapeutic pipeline.
AIVITA’s vaccine platform consist of autologous dendritic cells loaded with either (1) autologous tumor cells, or (2) multiple pathogen antigens for SARS-CoV-2, influenza, HPV, HSV, Dengue, malaria and meningitis, with more pathogens being added quarterly. This vaccine directs the patient’s own immune system to seek out and destroy the very cells responsible for the growth and spread of the cancer or pathogen. In cancer, AIVITA takes a unique pan-antigenic approach—targeting all neoantigens of tumor-initiating cells, rather than a select few — allowing the treatment to better target the cells responsible for the spread of cancer and overcome its tendency to mutate over time. The multi-pathogen vaccine targets multiple pathogens in one shot; sold as a kit, this platform technology can be rapidly adapted and scaled to meet emerging pathogens.
Based on clinical trial results showing tremendous promise in eradicating tumors without harmful side effects, the cancer technology has been cleared for an upcoming US-based Phase 2/3 clinical trial in glioblastoma and is the subject of a US-based Phase 1B clinical trial for melanoma with checkpoint inhibitors.